Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, and Lung Cancer Diagnosis and Treatment.
APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer
97P Multimodal AI models integrating clinical and CT imaging data to predict survival outcomes in immunotherapy-treated NSCLC: Results from the multicentric APOLLO11 study
242P Real-world safety and tolerability of adjuvant alectinib in resected ALK-positive NSCLC: Results from the Italian ATLAS registry
Surgical outcomes after neoadjuvant chemoimmunotherapy for resectable NSCLC: a systematic review and meta-analysis
Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM)
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis
Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC
Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective